Key result
High-risk Khorana scores predict ~14% VTE incidence in cancer patients receiving chemotherapy.
Why the study?
The utility of the Khorana score remains controversial due to varying results reported across different studies.
What is the incidence of VTE across different Khorana score risk strata in cancer patients receiving chemotherapy?
Population
5,852 cancer patients across 13 studies
Comparison
Different risk stratifications using the Khorana score
Design
Systematic review and meta-analysis
Authors
Loading...
Refines VTE risk estimates by Khorana strata in chemotherapy patients; extends prior data by separating DVT, PE, and bleeding incidences.
Meta-Analysis (n=5,852)
What is the incidence of VTE across different Khorana score risk strata in cancer patients receiving chemotherapy?
The Khorana score effectively stratifies VTE risk in cancer patients receiving chemotherapy, with the highest risk observed in the first 3-6 months.
Bao et al. (2021) conducted a meta-analysis in cancer patients receiving chemotherapy (n=5,852). Khorana score was evaluated on incidence of VTE. In cancer patients receiving chemotherapy, VTE incidence was 2% (95% CI 1-6%) in low-risk, 11% (95% CI 6-18%) in intermediate-risk, and 14% (95% CI 9-20%) in high-risk Khorana score groups.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: